Related Articles
MEK inhibitors against MET-amplified non-small cell lung cancer
Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells
Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells
Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib